from 2013 to 2017 in Nordic centers were prospectively included in the Nordic neuroendocrine carcinoma registry, according to inclusion criteria previously described 5 and outlined in Appendix 1.

A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC). Background: To compare the presenting and prognostic characteristics, cause-specific survival (CSS) rates, and ...